Comparison of Vasodilator Response of Inhaled Epoprostenol and Inhaled Nitric Oxide

• Status: Not yet recruiting
• Trial end date: 2022-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The overarching goal of this study is to examine the acute vasoreactive response to both inhaled nitric oxide and inhaled epoprostenol across both traditionally and non-traditionally interrogated phenotypes in PH, and to further characterize the relationship of vasoreactivity to disease severity and PH phenotype.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Brigham and Women's Hospital
• Treatments: Epoprostenol; Nitric Oxide; Tezosentan; Vasodilator Agents

Criteria

Inclusion Criteria:

• mPAP ≥ 21mmHg, PAWP ≤ 25mmHg, and PVR ≥3 WU

• Classified as WHO group I-III pulmonary hypertension

Exclusion Criteria:

• WHO group IV and V pulmonary hypertension

• Patients who are on baseline pulmonary vasodilator medications

• Severe aortic or mitral valve disease

• Patients who are pregnant

• Left ventricular ejection fraction of <35%

• Patients who are hospitalized as inpatients at the time of RHC

• Patients with systolic blood pressure <90mmHg or mean arterial pressure of < 60mmHg